A Fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis

Pooja Gupta, S.e. Thomas, J. Cory-Wright, Víctor Sebastián-Pérez, Ailidh Burgess, Emma Cattermole, C. Meghir, Chris Abell, Anthony G. Coyne, William R. Jacobs, Tom L. Blundell, Sangeeta Tiwari, V. MendesbioRxiv 2021 · DOI

TL;DR

Researchers have used a fragment-based drug discovery (FBDD) approach to identify potential inhibitors for key enzymes in the L-arginine biosynthesis pathway of Mycobacterium tuberculosis. This study reveals novel binding sites and potential drug candidates, highlighting the pathway as a promising target for new anti-tuberculosis therapies.

What Problem Does This Paper Address?

Tuberculosis (TB) remains a major global health threat, exacerbated by the rise of multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains. The L-arginine biosynthesis pathway in Mycobacterium tuberculosis has been identified as a promising target for anti-TB drug discovery because its disruption leads to bacterial sterilization. While some enzymes in this pathway have been explored, four key enzymes – ArgB, ArgC, ArgD, and ArgF – remained largely uninvestigated for their drug discovery potential. This paper aims to assess the "ligandability" of these enzymes, meaning their suitability for binding to small molecules that could act as inhibitors.

Methods

The study employed a multi-pronged approach, starting with Fragment-Based Drug Discovery (FBDD). This involved screening a library of 960 small, rule-of-three compliant fragments against the target enzymes.

The primary screening technique was Differential Scanning Fluorimetry (DSF), which measures changes in protein melting temperature upon fragment binding. Hits from DSF were then validated using a suite of biophysical and biochemical techniques:

  • Surface Plasmon Resonance (SPR): Used to confirm fragment binding and quantify binding kinetics.
  • Ligand-Observed NMR: Employed to study fragment binding and displacement interactions.
  • Isothermal Titration Calorimetry (ITC): Used to determine binding affinities (K<sub>d</sub>) of validated fragments.
  • Enzymatic Assays: To assess the inhibitory activity of fragments against the target enzymes.
  • X-ray Crystallography: Crucial for determining the three-dimensional structures of enzymes bound to fragments, providing detailed insights into binding modes and identifying novel binding sites.

Datasets

Not discussed in the paper. The study utilized an in-house library of 960 fragments for screening.

Key Insights and Ideas

  • Novel Allosteric Sites Identified: For ArgB and ArgF, fragments were found to bind to interfacial sites, distinct from the active site. This is particularly significant for ArgB, where binding to this new allosteric site leads to inhibition of enzymatic activity and growth inhibition of M. tuberculosis.
  • ArgB as a Promising Target: ArgB yielded the highest number of X-ray validated hits, and its inhibitors demonstrated on-target activity against M. tuberculosis growth, even in the presence of arginine.
  • ArgF's Interfacial Site Potential: ArgF also showed fragment binding at an interfacial site, close to the active site, suggesting a strategy to develop compounds that can bridge these regions for potent inhibition.
  • ArgD's PLP Dependence: Screening ArgD required careful consideration of its prosthetic group, PLP. The study found that the PLP-unsaturated form was more amenable to fragment screening, revealing potential binding interactions.
  • ArgC's Dual Binding Pockets: For ArgC, fragments were found to bind in both the substrate-binding and the NADP(H)-binding pockets, offering multiple avenues for inhibitor development.

Key Results

  • ArgB: Fourteen X-ray validated hits were identified, with two fragments (NMR711 and NMR446) showing significant inhibitory activity against M. tuberculosis growth and binding to a novel allosteric site.
  • ArgF: Eight X-ray validated hits were found, binding to an interfacial site.
  • ArgC: Four X-ray validated hits were identified, binding to either the substrate or cofactor binding sites.
  • ArgD: Two X-ray validated hits were identified, with binding occurring near the PLP binding site.
  • Inhibitory Activity: Compounds NMR711 and NMR446 demonstrated on-target inhibition of M. tuberculosis growth, with their activity being dependent on arginine availability, confirming their specificity for the arginine biosynthesis pathway.

Limitations and Future Work

  • ArgB Allosteric Site Hydrophobicity: The identified allosteric site in ArgB is highly hydrophobic, posing a challenge for developing small molecule inhibitors with improved potency due to limited opportunities for hydrogen bonding.
  • Conformational Changes in ArgB: The lack of observed conformational changes in ArgB crystal structures with bound fragments might be due to crystal packing constraints, and it's unclear if these changes occur in solution.
  • ArgF's Interfacial Site Development: While promising, developing inhibitors that anchor at ArgF's interfacial site and extend to the active site requires further investigation.
  • ArgD Selectivity: Achieving selectivity for ArgD might be challenging due to conserved active site residues with human orthologues.
  • Future Work: The authors propose ArgC and ArgF as particularly promising targets for dedicated drug discovery programs. Further optimization of fragment hits into larger, higher-affinity molecules is a clear next step. Investigating the potential promiscuity of NMR711, which showed activity regardless of arginine presence, is also warranted.

Summary updated

Abstract

Abstract The L-arginine biosynthesis pathway consists of eight enzymes that catalyse the conversion of L-glutamate to L-arginine, appears to be attractive target for anti-Tuberculosis (TB) drug discovery. Starvation of M. tuberculosis deleted for either argB or argF genes led to rapid sterilization of these strains in mice while Chemical inhibition of ArgJ with Pranlukast was also found to clear chronic M. tuberculosis infection in animal models. In this work, the ligandability of four enzymes of the pathway ArgB, ArgC, ArgD and ArgF is explored using a fragment-based approach. We reveal several hits for these enzymes validated with biochemical and biophysical assays, and X-ray crystallographic data, which in the case of ArgB were further confirmed to have on-target activity against M. tuberculosis . These results demonstrate the potential of more enzymes in this pathway to be targeted with dedicated drug discovery programmes.
BibTeX
@misc{gupta2021fragment,
  author = {Pooja Gupta and S.E. Thomas and J. Cory-Wright and Víctor Sebastián-Pérez and Ailidh Burgess and Emma Cattermole and C. Meghir and Chris Abell and Anthony G. Coyne and William R. Jacobs and Tom L. Blundell and Sangeeta Tiwari and V. Mendes},
  title = {{A Fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of <i>Mycobacterium tuberculosis</i>}},
  year = {2021},
  doi = {10.1101/2021.03.12.435067},
  howpublished = {bioRxiv},
}
Figure